ArticleCancer immunology, immunotherapy : CII2022

Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.

Bolun Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.